Nanosphere (NSPH) versus Its Competitors Head-To-Head Comparison

Nanosphere (NASDAQ: NSPH) is one of 78 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its rivals? We will compare Nanosphere to similar businesses based on the strength of its institutional ownership, profitability, dividends, analyst recommendations, valuation, risk and earnings.

Profitability

This table compares Nanosphere and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nanosphere -99.68% -232.37% -65.52%
Nanosphere Competitors -321.24% -23.41% -10.13%

Valuation & Earnings

This table compares Nanosphere and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nanosphere N/A N/A -0.31
Nanosphere Competitors $2.23 billion $244.34 million -84.68

Nanosphere’s rivals have higher revenue and earnings than Nanosphere. Nanosphere is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

52.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 17.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Nanosphere and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanosphere 0 0 0 0 N/A
Nanosphere Competitors 324 1965 3482 112 2.57

As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 3.31%. Given Nanosphere’s rivals higher possible upside, analysts clearly believe Nanosphere has less favorable growth aspects than its rivals.

Summary

Nanosphere rivals beat Nanosphere on 6 of the 8 factors compared.

Nanosphere Company Profile

Nanosphere, Inc. is engaged in developing, manufacturing and marketing an advanced molecular diagnostics platform, the Verigene System, which enables genomic and protein testing on a single platform. The Verigene System includes a molecular diagnostics workstation that is a single use consumable for testing. The Verigene System consists of a microfluidics processor, a touchscreen reader and disposable test cartridges. The Company is focused on the infectious disease diagnostics market. Its Infectious Disease Assays include Respiratory Virus with Sub-Typing (RV+); Respiratory Pathogens/Expanded Panel (RP Flex); Bloodstream Infection (BSI) Panels, which include Blood Culture – Gram Positive (BC-GP), Blood Culture – Gram Negative (BC-GN) and Blood Culture – Yeast (BC-Y); C. difficile (CDF), and Enteric Panel (EP). Its Human Pharmacogenetic Assays include Hypercoagulation (FV, FII, MTHFR Panel) and CYP2C19 Genetic Variance. It is focused on the infectious disease diagnostics market.

Receive News & Ratings for Nanosphere Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanosphere and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply